UNIV OF MISSOURI HEALTH CARE

Type: Teaching hospital
Where: COLUMBIA, MO
Medicare CCN: 260141
Received: $9,785,744 in 720 records, 2019 ($7,310,979 general, $2,474,765 research)
Source: CMS Open Payments search ↗

By year

Program year	Kind	Records	Amount
2019	General payment	319	$7,310,979
2019	Research payment	401	$2,474,765

By company

Company	Records	Amount	Years
Advanced Accelerator Applications	77	$5,545,825	2019
LANTHEUS MEDICAL IMAGING, INC.	17	$775,824	2019
TESARO, Inc.	18	$480,130	2019
Musculoskeletal Transplant Foundation Inc.	7	$444,829	2019
Merck Sharp & Dohme LLC	71	$242,786	2019
Arthrex, Inc.	14	$215,149	2019
BioMarin Pharmaceutical Inc.	51	$196,301	2019
JAZZ PHARMACEUTICALS INC.	1	$174,651	2019
Olympus Corporation of the Americas	3	$157,566	2019
B. Braun Medical Inc.	4	$133,305	2019
PFIZER INC.	21	$123,158	2019
Siemens Medical Solutions USA, Inc.	29	$96,038	2019
Mallinckrodt Enterprises LLC	5	$84,186	2019
Bayer Healthcare Pharmaceuticals Inc.	47	$74,722	2019
Alkermes, Inc.	55	$70,992	2019
Boston Scientific Corporation	7	$55,737	2019
AstraZeneca Pharmaceuticals LP	7	$55,098	2019
KCI USA, Inc.	6	$52,287	2019
CSL Behring	16	$48,297	2019
Ortho-Clinical Diagnostics, Inc.	8	$44,077	2019
Amgen Inc.	10	$42,367	2019
Baxter Healthcare	1	$41,700	2019
Dentsply Sirona Orthodontics Inc	3	$37,243	2019
Medical Device Business Services, Inc.	13	$36,307	2019
Covidien LP	7	$36,016	2019
Alcon Vision LLC	4	$34,285	2019
Optinose US, Inc.	3	$34,039	2019
Eli Lilly and Company	5	$32,325	2019
Ipsen Biopharmaceuticals, Inc	8	$31,071	2019
F. Hoffmann-La Roche AG	1	$29,670	2019
Abbott Laboratories	3	$26,970	2019
Roche Products Limited	12	$25,956	2019
Medtronic MiniMed, Inc.	3	$23,512	2019
Zimmer Biomet Holdings, Inc.	6	$20,916	2019
Stryker Corporation	15	$20,168	2019
Roche Diagnostics GmbH	3	$19,482	2019
Novartis Pharmaceuticals Corporation	7	$17,026	2019
ABBVIE INC.	4	$15,475	2019
Tandem Diabetes Care, Inc.	53	$14,450	2019
THERACHON HOLDING GMBH	3	$13,528	2019
Cumberland Pharmaceuticals, Inc.	1	$12,643	2019
Celgene Corporation	2	$12,019	2019
GUERBET LLC	1	$11,537	2019
Conformis, Inc.	5	$10,050	2019
E.R. Squibb & Sons, L.L.C.	3	$8,282	2019
Allergan, Inc.	2	$6,500	2019
GENZYME CORPORATION	9	$6,315	2019
Biogen, Inc.	2	$6,000	2019
Veran Medical Technologies, Inc.	2	$5,500	2019
Henry Schein, Inc.	1	$5,000	2019

By nature of payment

Nature	Records	Amount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	183	$6,479,884
Research payment	401	$2,474,765
Grant	41	$403,691
Royalty or License	8	$246,839
Space rental or facility fees (teaching hospital only)	64	$118,759
Consulting Fee	5	$33,355
Gift	8	$14,866
Education	8	$9,132
Charitable Contribution	1	$4,000
Honoraria	1	$450

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2019-12-31	Boehringer Ingelheim Pharmaceuticals, Inc.	$551	Research payment	In-kind items and services		Dose finding Trial in PPP Phase II	2019
2019-12-31	Edwards Lifesciences Corporation	$405	Education	In-kind items and services	EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring		2019
2019-12-31	Masimo Corporation	$371	Education	In-kind items and services	rainbow Acoustic Monitoring Device, Devices		2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$240	Research payment	In-kind items and services		MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial	2019
2019-12-31	Siemens Medical Solutions USA, Inc.	$195	Research payment	Cash or cash equivalent		UMissouri2018MRIPR529Beversdorf	2019
2019-12-31	Masimo Corporation	$171	Education	In-kind items and services	SET and rainbow SET Device, Devices		2019
2019-12-31	Masimo Corporation	$86	Education	In-kind items and services	rainbow Acoustic Monitoring Device, Devices		2019
2019-12-30	TESARO, Inc.	$26,762	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F	2019
2019-12-27	BioMarin Pharmaceutical Inc.	$1,310	Research payment	Cash or cash equivalent		Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondropl	2019
2019-12-20	JAZZ PHARMACEUTICALS INC.	$174,651	Research payment	Cash or cash equivalent	SUNOSI Drug, PAIN	SOLRIAMFETOL IN A MURINE MODEL OF SLEEP APNEA	2019
2019-12-20	B. Braun Medical Inc.	$12,393	Research payment	Cash or cash equivalent	CEFAZOLIN SODIUM Drug, INJECTIBLE DRUGS	SAFETY OF 1 G AND 2 G OF CEFAZOLIN IN PEDIATRIC SUBJECTS	2019
2019-12-19	B. Braun Medical Inc.	$101,821	Research payment	Cash or cash equivalent	CEFAZOLIN SODIUM Drug, INJECTIBLE DRUGS	SAFETY OF 1 G AND 2 G OF CEFAZOLIN IN PEDIATRIC SUBJECTS	2019
2019-12-19	Merck Sharp & Dohme LLC	$14,121	Research payment	Cash or cash equivalent	BRIDION Drug, NEUROSCIENCE	A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety ofSugammadex MK-8616 for the Rever	2019
2019-12-19	Arthrex, Inc.	$11,992	Research payment	Cash or cash equivalent	ARTHROPLASTY IMPLANTS SHOULDER ARTHROPLASTY & FRACTURE UNIVERS Device, ARTHROPLASTY	Arthrex SOS Total Shoulder Registry	2019
2019-12-19	B. Braun Medical Inc.	$5,359	Research payment	Cash or cash equivalent	CEFAZOLIN SODIUM Drug, INJECTIBLE DRUGS	SAFETY OF 1 G AND 2 G OF CEFAZOLIN IN PEDIATRIC SUBJECTS	2019
2019-12-19	Biogen, Inc.	$5,000	Grant	Cash or cash equivalent			2019
2019-12-19	Ipsen Biopharmaceuticals, Inc	$1,500	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysportabobotulinumt	2019
2019-12-18	Advanced Accelerator Applications	$33,750	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-12-18	Advanced Accelerator Applications	$33,275	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-12-18	Advanced Accelerator Applications	$28,717	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (4 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-12-18	Advanced Accelerator Applications	$28,540	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-12-18	Advanced Accelerator Applications	$21,140	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-12-18	Medtronic MiniMed, Inc.	$6,975	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Minimed 670G System Device, Durable Pump		2019
2019-12-18	PFIZER INC.	$3,030	Research payment	Cash or cash equivalent		DEVELOP SAMPLE PREP IMAGING AND ANALYSIS FOR AAV	2019
2019-12-17	Siemens Medical Solutions USA, Inc.	$8,059	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-12-17	Siemens Medical Solutions USA, Inc.	$5,330	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-12-17	Medical Device Business Services, Inc.	$2,976	Grant	Cash or cash equivalent			2019
2019-12-17	Siemens Medical Solutions USA, Inc.	$2,617	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-12-17	Bayer Healthcare Pharmaceuticals Inc.	$1,500	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-12-17	Siemens Medical Solutions USA, Inc.	$350	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-12-16	Bayer Healthcare Pharmaceuticals Inc.	$1,429	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-12-13	Bayer Healthcare Pharmaceuticals Inc.	$2,177	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-12-13	Conformis, Inc.	$1,700	Research payment	Cash or cash equivalent	iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS	iTotal 12-005	2019
2019-12-13	Bayer Healthcare Pharmaceuticals Inc.	$1,429	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-12-13	Bayer Healthcare Pharmaceuticals Inc.	$1,429	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-12-13	Bayer Healthcare Pharmaceuticals Inc.	$1,429	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-12-12	Amgen Inc.	$4,440	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Aranesp Biological, Nephrology		2019
2019-12-12	CSL Behring	$2,786	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-12-12	BioMarin Pharmaceutical Inc.	$326	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-12-12	CSL Behring	$65	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-12-11	ICU Medical Inc	$4,440	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-12-10	AstraZeneca Pharmaceuticals LP	$15,000	Grant	Cash or cash equivalent			2019
2019-12-10	BioMarin Pharmaceutical Inc.	$3,440	Research payment	Cash or cash equivalent		An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia	2019
2019-12-10	BioMarin Pharmaceutical Inc.	$2,175	Research payment	Cash or cash equivalent		A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111	2019
2019-12-10	BioMarin Pharmaceutical Inc.	$62	Research payment	Cash or cash equivalent		A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111	2019
2019-12-09	Merck Sharp & Dohme LLC	$6	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR	2019
2019-12-08	AstraZeneca Pharmaceuticals LP	$25,000	Grant	Cash or cash equivalent			2019
2019-12-05	Optinose US, Inc.	$9,687	Research payment	Cash or cash equivalent	OPN-375 Drug, Otolaryngology (Ear, Nose, Throat)	A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa	2019
2019-12-05	Shire North American Group Inc	$1,500	Research payment	Cash or cash equivalent	NATPARA (PARATHYROID HORMONE) Drug, INTERNAL MEDICINE	PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM	2019
2019-12-05	PFIZER INC.	$513	Research payment	Cash or cash equivalent	BAVENCIO Drug, ONCOLOGY	A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS	2019
2019-12-05	CSL Behring	$65	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-12-04	PFIZER INC.	$75,000	Research payment	Cash or cash equivalent		DEVELOPMENT OF CONTINUOUS FLOW SYNTHESIS OF VACCINE BIOCONJUGATES	2019
2019-12-04	BioMarin Pharmaceutical Inc.	$200	Research payment	Cash or cash equivalent	Kuvan Drug, PKU	PKU Demographics, Outcomes, and Safety Registry	2019
2019-12-03	Alkermes, Inc.	$985	Research payment	Cash or cash equivalent		Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831	2019
2019-12-02	Roche Diagnostics Corporation	$632	Consulting Fee	Cash or cash equivalent			2019
2019-11-27	LANTHEUS MEDICAL IMAGING, INC.	$77,059	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	QUADRAMET Drug, Radiopharmaceutical		2019
2019-11-27	Ortho-Clinical Diagnostics, Inc.	$18,306	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Clinical Chemistry Device, Diagnostics		2019
2019-11-27	Ortho-Clinical Diagnostics, Inc.	$2,787	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Clinical Chemistry Device, Diagnostics		2019
2019-11-27	Ortho-Clinical Diagnostics, Inc.	$400	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Clinical Chemistry Device, Diagnostics		2019
2019-11-26	ABBVIE INC.	$990	Research payment	Cash or cash equivalent		M15-741	2019
2019-11-26	Alkermes, Inc.	$112	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$112	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$112	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$97	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$77	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$42	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$28	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$22	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-26	Alkermes, Inc.	$9	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-11-25	Siemens Medical Solutions USA, Inc.	$7,000	Grant	Cash or cash equivalent			2019
2019-11-21	Arthrex, Inc.	$64,916	Research payment	Cash or cash equivalent	DISTAL EXTREMITIES SUTURE FIBERWIRE 2-0 Device, DISTAL EXTREMITIES	Canine Partial Rotator Cuff Treatment	2019
2019-11-20	Advanced Accelerator Applications	$26,250	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-11-20	Advanced Accelerator Applications	$24,790	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-11-20	Advanced Accelerator Applications	$24,250	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-11-20	Advanced Accelerator Applications	$21,140	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-11-20	Advanced Accelerator Applications	$3,750	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-11-19	Alcon Vision LLC	$9,285	Gift	In-kind items and services	Centurion Device, Ophthalmology		2019
2019-11-19	BioMarin Pharmaceutical Inc.	$2,000	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-11-18	Alkermes, Inc.	$221	Research payment	In-kind items and services		Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831	2019
2019-11-15	Cumberland Pharmaceuticals, Inc.	$12,643	Research payment	Cash or cash equivalent		IFE-MTA	2019
2019-11-15	Covidien LP	$10,000	Grant	Cash or cash equivalent			2019
2019-11-15	THERACHON HOLDING GMBH	$5,000	Research payment	Cash or cash equivalent		A MULTICENTER PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY TO INVESTIGATE THE CLINICAL AND ANTHROPOMETRIC CHARACTERISTIC	2019
2019-11-15	THERACHON HOLDING GMBH	$2,500	Research payment	Cash or cash equivalent		A MULTICENTER PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY TO INVESTIGATE THE CLINICAL AND ANTHROPOMETRIC CHARACTERISTIC	2019
2019-11-15	Bayer Healthcare Pharmaceuticals Inc.	$1,429	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-11-14	BioMarin Pharmaceutical Inc.	$12,100	Research payment	Cash or cash equivalent		An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia	2019
2019-11-14	Bayer Healthcare Pharmaceuticals Inc.	$10,118	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-11-14	CSL Behring	$750	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-11-14	CSL Behring	$490	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-11-13	Olympus Corporation of the Americas	$81,895	Grant	In-kind items and services	Olympus EMR & ESD Devices Device, EndoTherapy Products		2019
2019-11-08	Bayer Healthcare Pharmaceuticals Inc.	$1,429	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-11-08	Bayer Healthcare Pharmaceuticals Inc.	$1,429	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-11-07	GUERBET LLC	$11,537	Research payment	Cash or cash equivalent		Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging	2019
2019-11-07	CSL Behring	$11,221	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-11-07	BioMarin Pharmaceutical Inc.	$9,274	Research payment	Cash or cash equivalent		A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111	2019
2019-11-07	Ipsen Biopharmaceuticals, Inc	$2,591	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysportabobotulinumt	2019
2019-11-07	Stryker Corporation	$2,095	Research payment	Cash or cash equivalent	TRIATHLON Device, KNEES	TRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY	2019
2019-11-07	Novocure Inc.	$1,750	Research payment	Cash or cash equivalent	Optune Device, Oncology	EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b	2019
2019-11-07	CSL Behring	$588	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-11-07	Arthrex, Inc.	$102	Royalty or License	Cash or cash equivalent			2019
2019-11-06	Bayer Healthcare Pharmaceuticals Inc.	$1,960	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-11-06	Bayer Healthcare Pharmaceuticals Inc.	$1,286	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-11-05	Musculoskeletal Transplant Foundation Inc.	$110,311	Research payment	Cash or cash equivalent		Clinical Assessment of the Missouri Osteochondral Allograft Preservation System - MOPS	2019
2019-11-05	TESARO, Inc.	$26,762	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F	2019
2019-11-05	Merck Sharp & Dohme LLC	$26,175	Research payment	Cash or cash equivalent	LENVIMA Drug, ONCOLOGY	A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat	2019
2019-11-05	Ipsen Biopharmaceuticals, Inc	$4,611	Research payment	Cash or cash equivalent	DYSPORT Drug, Neurology	APhase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysportabobotulinumt	2019
2019-11-05	Alkermes, Inc.	$601	Research payment	Cash or cash equivalent		Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831	2019
2019-11-04	GlaxoSmithKline, LLC.	$1,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	NUCALA Biological, RESPIRATORY		2019
2019-11-02	Olympus Corporation of the Americas	$70,670	Grant	In-kind items and services	Olympus Capital Accessories Device, GI & Respiratory Products		2019
2019-11-01	Boston Scientific Corporation	$21,054	Grant	In-kind items and services	GENERAL - METAL STENTS - G.I. Device, STENTS		2019
2019-11-01	Boston Scientific Corporation	$17,668	Grant	In-kind items and services	GENERAL - BILIARY DEVICES Device, BILIARY DEVICES		2019
2019-11-01	Boston Scientific Corporation	$9,798	Grant	In-kind items and services	GENERAL - HEMOSTASIS Device, HEMOSTASIS		2019
2019-11-01	Medical Device Business Services, Inc.	$2,000	Grant	Cash or cash equivalent			2019
2019-11-01	Boston Scientific Corporation	$1,556	Grant	In-kind items and services	GENERAL - POLYPECTOMY Device, POLYPECTOMY		2019
2019-11-01	GENZYME CORPORATION	$1,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	DUPIXENT Drug, IMMUNOLOGY		2019
2019-11-01	Novartis Pharmaceuticals Corporation	$1,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	XOLAIR Biological, RESPIRATORY		2019
2019-11-01	Boston Scientific Corporation	$661	Grant	In-kind items and services	GENERAL - GI DILATATION Device, GI DILATION		2019
2019-10-31	LANTHEUS MEDICAL IMAGING, INC.	$61,417	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	QUADRAMET Drug, Radiopharmaceutical		2019
2019-10-31	Bayer Healthcare Pharmaceuticals Inc.	$524	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-10-31	Alkermes, Inc.	$85	Research payment	In-kind items and services	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-10-31	Bayer Healthcare Pharmaceuticals Inc.	$61	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-10-29	Merck Sharp & Dohme LLC	$21,652	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat	2019
2019-10-29	Merck Sharp & Dohme LLC	$818	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat	2019
2019-10-29	Merck Sharp & Dohme LLC	$806	Research payment	Cash or cash equivalent	BRIDION Drug, NEUROSCIENCE	A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety ofSugammadex MK-8616 for the Rever	2019
2019-10-29	Merck Sharp & Dohme LLC	$545	Research payment	In-kind items and services	LENVIMA Drug, ONCOLOGY	A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat	2019
2019-10-29	BioMarin Pharmaceutical Inc.	$543	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-10-28	Bayer Healthcare Pharmaceuticals Inc.	$6,629	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-10-25	Advanced Accelerator Applications	$96,280	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$92,800	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$87,000	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$87,000	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$82,650	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$60,175	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$36,550	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$34,640	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$30,000	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$24,060	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$22,500	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-25	Advanced Accelerator Applications	$21,140	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-10-24	TESARO, Inc.	$7,217	Research payment	Cash or cash equivalent	ZEJULA Drug, ONCOLOGY	PHASE 2, A STUDY OF NIRAPARIB COMBINED WITH BEVACIZUMAB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER F	2019
2019-10-23	Conformis, Inc.	$1,600	Research payment	Cash or cash equivalent	iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS	iTotal 12-005	2019
2019-10-23	Conformis, Inc.	$1,500	Research payment	Cash or cash equivalent	iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS	iTotal 12-005	2019
2019-10-22	Musculoskeletal Transplant Foundation Inc.	$46,796	Royalty or License	Cash or cash equivalent			2019
2019-10-22	Merck Sharp & Dohme LLC	$10,770	Research payment	Cash or cash equivalent	BRIDION Drug, NEUROSCIENCE	A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety ofSugammadex MK-8616 for the Rever	2019
2019-10-18	Covidien LP	$1,447	Research payment	Cash or cash equivalent	Parietene Device, Hernia Repair	PPDS	2019
2019-10-17	Musculoskeletal Transplant Foundation Inc.	$46,796	Royalty or License	Cash or cash equivalent			2019
2019-10-17	Roche Products Limited	$5,682	Research payment	Cash or cash equivalent	Xolair Biological, Immunology	OPEN LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS	2019
2019-10-17	Allergan, Inc.	$1,500	Education	Cash or cash equivalent			2019
2019-10-16	ABBVIE INC.	$11,985	Research payment	Cash or cash equivalent		M15-741	2019
2019-10-16	Alkermes, Inc.	$46	Research payment	In-kind items and services		Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831	2019
2019-10-15	Boehringer Ingelheim International GmbH	$0	Research payment	In-kind items and services		Comparative study in Psoriasis	2019
2019-10-11	Medical Device Business Services, Inc.	$3,220	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-10-10	Arthrex, Inc.	$13,014	Research payment	Cash or cash equivalent	BIOLOGICS CONSUMABLES BIOLOGICS SYNTHETIC BONE GRAFT Biological, BIOLOGICS	Investigator Driven, Multi-Centered, Superior Capsular Reconstruction Study	2019
2019-10-10	BioMarin Pharmaceutical Inc.	$1,450	Research payment	Cash or cash equivalent		An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia	2019
2019-10-10	CSL Behring	$285	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-10-10	CSL Behring	$65	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019
2019-10-09	Olympus Corporation of the Americas	$5,000	Grant	Cash or cash equivalent			2019
2019-10-09	Bayer Healthcare Pharmaceuticals Inc.	$1,960	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-10-09	Bayer Healthcare Pharmaceuticals Inc.	$1,960	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-10-09	C. R. Bard, Inc. & Subsidiaries	$1,599	Gift	In-kind items and services	ARCTIC SUN Device, MEDICAL SYSTEMS		2019
2019-10-09	C. R. Bard, Inc. & Subsidiaries	$1,599	Gift	In-kind items and services	ARCTIC SUN Device, MEDICAL SYSTEMS		2019
2019-10-09	C. R. Bard, Inc. & Subsidiaries	$1,599	Gift	In-kind items and services	ARCTIC SUN Device, MEDICAL SYSTEMS		2019
2019-10-09	Bayer Healthcare Pharmaceuticals Inc.	$1,286	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-10-09	Bayer Healthcare Pharmaceuticals Inc.	$1,286	Research payment	Cash or cash equivalent	Non-Covered	BAY94-8862 ph 3 conventional in diabetic nephropathy	2019
2019-10-08	BioMarin Pharmaceutical Inc.	$8,163	Research payment	Cash or cash equivalent		An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia	2019
2019-10-08	BioMarin Pharmaceutical Inc.	$7,083	Research payment	Cash or cash equivalent		An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia	2019
2019-10-08	Siemens Medical Solutions USA, Inc.	$5,245	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-10-08	Siemens Medical Solutions USA, Inc.	$2,617	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-10-08	Siemens Medical Solutions USA, Inc.	$590	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-10-08	Avita Medical Americas, LLC	$450	Honoraria	Cash or cash equivalent			2019
2019-10-08	Siemens Medical Solutions USA, Inc.	$350	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-10-07	Optinose US, Inc.	$14,714	Research payment	Cash or cash equivalent	OPN-375 Drug, Otolaryngology (Ear, Nose, Throat)	A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Sa	2019
2019-10-03	LANTHEUS MEDICAL IMAGING, INC.	$79,983	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	QUADRAMET Drug, Radiopharmaceutical		2019
2019-10-03	BioMarin Pharmaceutical Inc.	$62	Research payment	Cash or cash equivalent		A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111	2019
2019-09-30	THERACHON HOLDING GMBH	$6,028	Research payment	In-kind items and services		A MULTICENTER PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY TO INVESTIGATE THE CLINICAL AND ANTHROPOMETRIC CHARACTERISTIC	2019
2019-09-30	Alkermes, Inc.	$1,528	Research payment	Cash or cash equivalent	OLANZAPINE Drug, CNS	A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc	2019
2019-09-30	Mallinckrodt Enterprises LLC	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE		2019
2019-09-30	BioMarin Pharmaceutical Inc.	$1,100	Research payment	Cash or cash equivalent		Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondropl	2019
2019-09-30	Alkermes, Inc.	$986	Research payment	Cash or cash equivalent		Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831	2019
2019-09-27	SOBI, INC	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Kineret Drug, Immunology		2019
2019-09-27	Novartis Pharmaceuticals Corporation	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ILARIS Biological, IMMUNOLOGY		2019
2019-09-26	Medical Device Business Services, Inc.	$1,369	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-09-25	Advanced Accelerator Applications	$65,250	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Advanced Accelerator Applications	$54,375	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Advanced Accelerator Applications	$46,980	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Advanced Accelerator Applications	$37,125	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Advanced Accelerator Applications	$22,128	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Advanced Accelerator Applications	$19,980	Compensation for services other than consulting, including serving as faculty or as a speaker at a v (2 payments)	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Advanced Accelerator Applications	$12,140	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Advanced Accelerator Applications	$10,875	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	LUTATHERA Drug, Oncology		2019
2019-09-25	Tandem Diabetes Care, Inc.	$250	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	t-slim insulin pump Device, Endocrinology		2019
2019-09-25	Tandem Diabetes Care, Inc.	$250	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	t-slim insulin pump Device, Endocrinology		2019
2019-09-25	Tandem Diabetes Care, Inc.	$250	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	t-slim insulin pump Device, Endocrinology		2019
2019-09-24	Roche Diagnostics GmbH	$8,500	Research payment	Cash or cash equivalent	CD cobas Reagents Device, Centralized Diagnostics	no study name	2019
2019-09-24	Zimmer Biomet Holdings, Inc.	$3,000	Grant	Cash or cash equivalent	Grants Device, General		2019
2019-09-24	BioMarin Pharmaceutical Inc.	$2,520	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-09-19	Merck Sharp & Dohme LLC	$10,637	Research payment	Cash or cash equivalent	BRIDION Drug, NEUROSCIENCE	A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety ofSugammadex MK-8616 for the Rever	2019
2019-09-19	Medtronic MiniMed, Inc.	$6,462	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Minimed 670G System Device, Durable Pump		2019
2019-09-18	KCI USA, Inc.	$15,363	Research payment	Cash or cash equivalent	PREVENA Device, NON-COVERED	KCI.PREVENA.2017.01 Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Inci	2019
2019-09-18	KCI USA, Inc.	$10,932	Research payment	Cash or cash equivalent	PREVENA Device, NON-COVERED	KCI.PREVENA.2017.01 Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Inci	2019
2019-09-17	CSL Behring	$10,727	Research payment	Cash or cash equivalent		Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II	2019

The latest 200 records of 720.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Columbia, MO, county Boone County, MO, state Missouri; placed by its city name.

Measure	Place (city or town) Columbia, MO	County Boone County, MO	State Missouri
Population B01003	128,548	188,043	6,191,814
Population, 2020 census P1	126,254	183,610	6,154,913
Median age B01002	29.5	32.7	39.0
Under 18 B01001	18.7%	20.1%	22.3%
65 and over B01001	11.6%	13.5%	17.9%
Households B11001	52,564	76,562	2,508,227
Foreign born B05002	8.1%	6.4%	4.5%
Median household income B19013	$66,498	$72,758	$70,702
Median family income B19113	$106,412	$104,323	$91,360
Per capita income B19301	$39,340	$40,954	$39,695
Poverty rate B17001	19.3%	16.6%	12.6%
Unemployment rate B23025	4.0%	3.8%	4.0%
Civilian labor force B23025	70,686	102,651	3,120,639
Mean commute (minutes) B08013	16.4	18.7	23.5
Bachelor's degree or higher B15003	56.7%	51.5%	32.4%
Housing units B25001	56,054	81,675	2,825,287
Owner-occupied B25003	48.7%	57.7%	68.1%
Renters B25003	51.3%	42.3%	31.9%
Median home value B25077	$284,600	$272,800	$230,300
Median gross rent B25064	$1,097	$1,088	$1,033
White, not Hispanic B03002	71.7%	75.8%	76.3%
Black B03002	12.1%	9.5%	10.9%
Hispanic or Latino B03002	4.4%	4.5%	5.2%
Asian B03002	6.3%	4.8%	2.1%
American Indian and Alaska Native B03002	0.1%	0.1%	0.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Columbia, MO.